Collection of Maternal Blood Samples for Development of Non-invasive Prenatal Diagnostic Testing
Status: | Recruiting |
---|---|
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 3/30/2013 |
Start Date: | February 2012 |
Contact: | Nina Wemmer, MS, CGC |
Email: | info@natera.com |
Phone: | 650-249-9090 |
Prenatal Diagnosis of Fetal DNA Isolated From Maternal Plasma
The purpose of this study is to collect blood samples from pregnant women who achieved
pregnancy following in-vitro fertilization (IVF) with Natera's preimplantation aneuploidy
screening (with or without single gene gene testing). These samples will be used for test
development of non-invasive prenatal diagnostic testing.
Eligible subjects will sign a consent form and have blood drawn at approximately 8-17 weeks
gestation. Subjects will received $200 reimbursement for providing this blood sample. The
collected samples will be used to help develop non-invasive prenatal diagnostic testing
using Natera's Parental Support technology which is already commercialized for genetic
diagnosis of in-vitro embryos. In this study, the technology will be tested for it's ability
to analyze fetal-specific pieces of DNA isolated from the mother's blood. No results of the
maternal blood testing will be reported to the subject or to their physicians.
Inclusion Criteria:
- Pregnant women willing to donate a blood sample during the first or second trimester
of their pregnancy (approximately 8-17 weeks gestation)
- Use of Natera (formerly Gene Security Network)'s commercial preimplantation genetic
testing (PGS/PGD)to achieve the current pregnancy
Exclusion Criteria:
- Pregnant women who did not use Natera (formerly Gene Security Network)'s PGS/PGD
testing to achieve their current pregnancy
We found this trial at
1
site
Click here to add this to my saved trials